ACVR2B and cancer: Among the myriad factors known to contribute to skeletal muscle wasting resulting from cancer progression, members of the transforming growth factor (TGF)‐β superfamily, signalling via their binding to the activin receptor type 2B (ACVR2B), have received much attention.